Hormonal regulation plays a key role in determining bone mass in humans. Both skeletal growth and bone loss in health and disease is critically controlled by endocrine factors and low bone mass is a feature of both excess and deficiency of a broad range of hormones. This article explores the impact of diabetes and thyroid, parathyroid, sex steroid and growth hormone disorders on bone mass and fracture risk. Evidence for current management strategies is provided along with suggested practice points and gaps in knowledge for future research.
|Tidsskrift||Best Practice and Research in Clinical Endocrinology and Metabolism|
|Tidlig onlinedato||21 jan. 2022|
|Status||Udgivet - mar. 2022|